Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CHECKPOINT INHIBITION

Checkpoint inhibition: NK cells enter the scene

Tumor-associated natural killer cells have elevated expression of the checkpoint inhibitory receptor TIGIT. Monoclonal antibody–mediated blockade targeting TIGIT unleashes the anti-tumor activity of both natural killer cells and T cells in preclinical mouse models and efficiently delays tumor growth.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Mode of action of the blockade of TIGIT in anti-tumor immunity.

Marina Corral Spence/Springer Nature

References

  1. Zhang, Q. et al. Nat. Immunol. https://doi.org/10.1038/s41590-018-0132-0 (2018)

  2. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. & Smyth, M. J. Clin. Cancer Res. 22, 5183–5188 (2016).

    Article  PubMed  CAS  Google Scholar 

  3. Stanietsky, N. et al. Proc. Natl Acad. Sci. USA 106, 17858–17863 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Johnston, R. J. et al. Cancer Cell 26, 923–937 (2014).

    Article  PubMed  CAS  Google Scholar 

  5. Yu, X. et al. Nat. Immunol. 10, 48–57 (2009).

    Article  PubMed  CAS  Google Scholar 

  6. Cerwenka, A. & Lanier, L. L. Nat. Rev. Immunol. 16, 112–123 (2016).

    Article  PubMed  CAS  Google Scholar 

  7. Chiossone, L., Vienne, M., Kerdiles, Y. M. & Vivier, E. Semin. Immunol. 31, 55–63 (2017).

    Article  PubMed  CAS  Google Scholar 

  8. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. & Cerwenka, A. J. Immunol. 192, 4184–4191 (2014).

    Article  PubMed  CAS  Google Scholar 

  9. Della Chiesa, M. et al. Front. Immunol 7, 351 (2016).

    PubMed  PubMed Central  Google Scholar 

  10. Stojanovic, A., Correia, M. P. & Cerwenka, A. Cancer Microenviron 6, 135–146 (2013).

    Article  PubMed  CAS  Google Scholar 

  11. Blake, S. J. et al. Cancer Discov 6, 446–459 (2016).

    Article  PubMed  CAS  Google Scholar 

  12. Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & van Hall, T. Curr. Opin. Immunol. 39, 44–51 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adelheid Cerwenka.

Ethics declarations

Competing interests

A.C. is a member of the scientific advisory board of Dragonfly Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stojanovic, A., Cerwenka, A. Checkpoint inhibition: NK cells enter the scene. Nat Immunol 19, 650–652 (2018). https://doi.org/10.1038/s41590-018-0142-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-018-0142-y

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing